A Search Service for Abbreviation / Long Form

■ Related PubMed/MEDLINE Info.

[Related PubMed/MEDLINE]
Total Number of Papers: 131
[Display Entries]
100 entries :
      (Publication year, Descending)
100 entries :
      (Publication year, Ascending)
all entries
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation : BTcP
Long Form : breakthrough cancer pain
No. Year Title Co-occurring Abbreviation
2022 3-T magnetic resonance-guided high-intensity focused ultrasound (3 T-MR-HIFU) for the treatment of pain from bone metastases of solid tumors. 3T-MR-HIFU, BM, QoL, SREs
2022 Analyzing Differences in Perception between Oncologists and Patients to Adapt Pharmacological Treatment for Breakthrough Cancer Pain: Observational ADAPTATE Study. TF
2022 Bibliometric Network Analysis on Rapid-Onset Opioids for Breakthrough Cancer Pain Treatment. WoS
2022 Clinical Practice Guidelines in the Management of Breakthrough Cancer Pain: A Systematic Review using the Appraisal of Guidelines for Research and Evaluation (AGREE II) Instrument. CPGs, ICC
2022 Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care. QoL
2022 Patients' Satisfaction with Breakthrough Cancer Pain Therapy: A Secondary Analysis of IOPS-MS Study. OR
2021 Characterizing Breakthrough Cancer Pain Using Ecological Momentary Assessment with a Smartphone App: Feasibility and Clinical Findings. apps, EMA
2021 CT-Guided Coeliac Plexus Neurolysis in Patients with Intra-Abdominal Malignancy: A Retrospective Evaluation of 52 Palliative In-Patients. CAP, CPB, CPN
2021 Cultural adaptation and psychometric validation of the Portuguese breakthrough pain assessment tool with cancer patients. BAT, BAT, re
10  2021 Current management of cancer pain in Italy: Expert opinion paper. ---
11  2021 Effect of a theory-driven educational intervention on the level of knowledge, attitudes, and assessment practices regarding breakthrough cancer pain (BTCP) management among medical nurses in Hong Kong. ---
12  2021 Impact of individualized management of breakthrough cancer pain on quality of life in advanced cancer patients: CAVIDIOPAL study. QoL
13  2021 Multidimensional Statistical Technique for Interpreting the Spontaneous Breakthrough Cancer Pain Phenomenon. A Secondary Analysis from the IOPS-MS Study. IOPS-MS, MCA, NP-BTcP
14  2021 Oxycodone/Acetaminophen: The Tailoring Combination Treatment for Specific Clinical Profile of Opioid Well-Responsive Cancer Pain. BGP, IOPS-MS, NRS
15  2021 The Italian Questionnaire for Cancer Breakthrough Pain Diagnosis, a Multicenter Validation Study. BPI, IQ-BTP
16  2021 The Prevalence and Characteristics of Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain. OME
17  2021 Understanding the Chameleonic Breakthrough Cancer Pain. ---
18  2021 What to Do and What Not to Do in the Management of Cancer Pain: A Physician Survey and Expert Recommendations. ---
19  2020 Breakthrough Cancer Pain Clinical Features and Differential Opioids Response: A Machine Learning Approach in Patients With Cancer From the IOPS-MS Study. ---
20  2020 Breakthrough cancer pain in 2020. ---
21  2020 Breakthrough cancer pain treatment in Spain: physicians' perception of current opioids utilization and prescription. ROOs
22  2020 Breakthrough cancer pain: review and calls to action to improve its management. ---
23  2020 Breakthrough Pain in Patients with Lung Cancer. A Secondary Analysis of IOPS MS Study. ---
24  2020 Careful Breakthrough Cancer Pain Treatment through Rapid-Onset Transmucosal Fentanyl Improves the Quality of Life in Cancer Patients: Results from the BEST Multicenter Study. ESAS, HRQoL, PSQI
25  2020 Drug utilization study on immediate release Fentanyl in Spain. Prevalence, incidence, and indication. IRF
26  2020 Interference with daily functioning by breakthrough pain in patients with cancer. BPI, IDF, NRS, QoL
27  2020 Patient Satisfaction with Fentanyl Pectin Nasal Spray in Breakthrough Cancer Pain Management During Radiotherapy for Head and Neck Cancer. FPNS
28  2020 The role of fentanyl in the treatment of breakthrough cancer pain: Different biotechnologies, different results and different drug costs. FBT, INFS, OTFC
29  2020 [Status and Rationality of Opioid Use in Lung Cancer Patients: A Single Center Retrospective Study]. DDC
30  2019 Breakthrough Cancer Pain in Patients Receiving Low Doses of Opioids for Background Pain. OME
31  2019 Breakthrough Cancer Pain in Patients With Abdominal Visceral Cancer Pain. ---
32  2019 Current management of breakthrough cancer pain according to physicians from pain units in Spain. ---
33  2019 Development and Testing of a Mobile App for Pain Management Among Cancer Patients Discharged From Hospital Treatment: Randomized Controlled Trial. QoL
34  2019 Effectiveness of fentanyl pectin nasal citrate in controlling episodes of breakthrough cancer pain triggered by routine radiotherapy procedures. FPNS, VAS
35  2019 Effects of Age Among Elderly Cancer Patients on Breakthrough Pain Management with Sublingual Fentanyl Tablets. AEs, MCS, PCS, PI, SF-12v2, SFTs
36  2019 Expert consensus on the management of breakthrough cancer pain in older patients. A Delphi study. ---
37  2019 Is pain part of a systemic syndrome in head and neck cancer? HNC
38  2019 Prevalence and characterization of breakthrough pain in cancer patients with proctalgia treated with 3D pelvic radiotherapy. ---
39  2019 Real-life management of patients with breakthrough cancer pain caused by bone metastases in Spain. PC
40  2019 Usability, Acceptability, and Usefulness of an mHealth App for Diagnosing and Monitoring Patients With Breakthrough Cancer Pain. ---
41  2019 Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts. IQR, MED
42  2018 Active study: undetected prevalence and clinical inertia in the treatment of breakthrough cancer pain (BTcP). ---
43  2018 Breakthrough cancer pain (BTcP) management: a review of international and national guidelines. ---
44  2018 Breakthrough Cancer Pain Influences General Activities and Pain Management: A Comparison of Patients with and without Breakthrough Cancer Pain. PPGs
45  2018 Breakthrough cancer pain tailored treatment: which factors influence the medication choice? An observational, prospective and cross-sectional study in patients with terminal cancer. OM, TIRF
46  2018 Breakthrough cancer pain: The importance of the right treatment at the right time. HCPs
47  2018 Factors influencing the use of opioids for breakthrough cancer pain: A secondary analysis of the IOPS-MS study. ---
48  2018 Non pharmacological interventions and non-fentanyl pharmacological treatments for breakthrough cancer pain: A systematic and critical review. ---
49  2018 Prevalence and characteristics of breakthrough cancer pain in an outpatient clinic in a Catalan teaching hospital: incorporation of the Edmonton Classification System for Cancer pain into the diagnostic algorithm. ECS-CP
50  2018 The use of fentanyl in pain management in head and neck cancer patients: a narrative review. TTS
51  2018 Treating breakthrough pain in oncology. ---
52  2017 Assessment and treatment of breakthrough cancer pain: from theory to clinical practice. ROO
53  2017 Breakthrough cancer pain and rational drug use. ---
54  2017 Breakthrough Cancer Pain Is Associated with Spinal Gap Junction Activation via Regulation of Connexin 43 in a Mouse Model. Cx, GFAP, GJ, p-Cx43
55  2017 Cost-effectiveness analysis of oral fentanyl formulations for breakthrough cancer pain treatment. OFFs, QALYs
56  2017 Fentanyl buccal tablet for breakthrough cancer pain in clinical practice: results of the non-interventional prospective study ErkentNIS. FBT, NRS
57  2017 High dosage of a fixed combination oxycodone/naloxone prolonged release: efficacy and tolerability in patients with chronic cancer pain. QoL
58  2017 Oncologist's knowledge and implementation of guidelines for breakthrough cancer pain in Spain: CONOCE study. CPG, SEOM
59  2016 Breakthrough Cancer Pain: Ten Commandments. ---
60  2016 Breakthrough cancer pain: twenty-five years of study. ---
61  2016 Consensus and controversies in the definition, assessment, treatment and monitoring of BTcP: results of a Delphi study. ---
62  2016 Efficacy, safety, and tolerability of fentanyl pectin nasal spray in patients with breakthrough cancer pain. FPNS
63  2016 Erratum to: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. ---
64  2016 Fentanyl citrate sublingual formulation (Vellofent) for quick BTcP hindering. ---
65  2016 Fentanyl Pectin Nasal Spray Versus Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management ofBreakthrough Cancer Pain: A Comparative Study. FPNS, OM
66  2016 Fentanyl sublingual spray for breakthrough cancer pain in patients receiving transdermal fentanyl. ATC, FSS, TFP
67  2016 From "Breakthrough" to "Episodic" Cancer Pain? A European Association for Palliative Care Research Network Expert Delphi Survey Toward a Common Terminology and Classification of Transient Cancer Pain Exacerbations. ---
68  2016 Long-term safety of fentanyl sublingual spray in opioid-tolerant patients with breakthrough cancer pain. AEs
69  2016 Practice Patterns in Distinguishing Between Background Pain and Breakthrough Pain During Patient Education: a Korean Physician Survey. CI, OR
70  2016 Reply-Letter to the Editor: What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. ---
71  2016 What to Do, and What Not to Do, When Diagnosing and Treating Breakthrough Cancer Pain (BTcP): Expert Opinion. ---
72  2015 A Korean Nationwide Survey for Breakthrough Cancer Pain in an Inpatient Setting. BCP
73  2015 A new once-a-day fentanyl citrate patch (Fentos Tape) could be a new treatment option in patients with end-of-dose failure using a 72-h transdermal fentanyl matrix patch. PI
74  2015 Accuracy of a Diagnostic Algorithm to Diagnose Breakthrough Cancer Pain as Compared With Clinical Assessment. ---
75  2015 An Observational Research Study to Evaluate the Impact of Breakthrough Cancer Pain on the Daily Lives and Functional Status of Patients. ---
76  2015 Breakthrough pain and its treatment: critical review and recommendations of IOPS (Italian Oncologic Pain Survey) expert group. IOPS
77  2015 Comparing the effectiveness of intranasal fentanyl spray with oral transmucosal fentanyl citrate in breakthrough pain. INFS, OTFC
78  2015 Diagnosis and management of breakthrough cancer pain: Have all the questions been resolved? A Delphi-based consensus assessment (DOIRON). ---
79  2015 Effective Dose Titration of Fentanyl Sublingual Spray in Patients With Breakthrough Cancer Pain. AE
80  2015 Fentanyl Buccal Tablet vs. Oral Morphine in Doses Proportional to the Basal Opioid Regimen for the Management of Breakthrough Cancer Pain: A Randomized, Crossover, Comparison Study. FBTs, OM
81  2015 Improved patient functioning after treatment of breakthrough cancer pain: an open-label study of fentanyl buccal tablet in patients with cancer pain. FBT, PGIC
82  2015 Transmucosal Immediate-Release Fentanyl for Breakthrough Cancer Pain: Opportunities and Challenges for Use in Palliative Care. TIRF
83  2014 Breakthrough cancer pain (BTcP): a synthesis of taxonomy, pathogenesis, therapy, and good clinical practice in adult patients in Italy. BP, ROO
84  2014 Breakthrough cancer pain: the current situation. ---
85  2014 Cost-effectiveness analysis of transnasal fentanyl citrate for the treatment of breakthrough cancer pain. ---
86  2014 Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. OM, OM, SLF, SLF, VAS
87  2014 Lack of correlation between the effective dose of fentanyl sublingual spray for breakthrough cancer pain and the around-the-clock opioid dose. AEs, ATC, rs
88  2014 Patient Satisfaction with Fentanyl Sublingual Spray in Opioid-Tolerant Patients with Breakthrough Cancer Pain. AE, SE, TSQM
89  2014 Rapid-onset opioids for the treatment of breakthrough cancer pain: two cases of drug abuse. ---
90  2014 Safety and efficacy of oral transmucosal fentanyl citrate compared to morphine sulphate immediate release tablet in management of breakthrough cancer pain. NRS, OTFC
91  2013 A network meta-analysis of the efficacy of opioid analgesics for the management of breakthrough cancer pain episodes. INFS, PID
92  2013 Breakthrough pain in patients with abdominal cancer pain. ---
93  2013 Budget impact analysis of the fentanyl buccal tablet for treatment of breakthrough cancer pain. ---
94  2013 Efficacy and safety of sublingual fentanyl orally disintegrating tablets in patients with breakthrough pain: multicentre prospective study. AEs, BTncP, BTP, sublingual fentanyl ODT, VAS
95  2013 Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. FBT, ODT, OTFC
96  2013 European Oncology Nursing Society breakthrough cancer pain guidelines. ---
97  2013 Fentanyl for the treatment of tumor-related breakthrough pain. RCTs
98  2013 How nurses assess breakthrough cancer pain, and the impact of this pain on patients' daily lives--results of a European survey. ---
99  2013 Opioid use and effectiveness of its prescription at discharge in an acute pain relief and palliative care unit. ---
100  2013 Pharmacokinetics and dose proportionality of fentanyl sublingual spray: a single-dose 5-way crossover study. AEs, AUClast, tmax